Samsung Biologics and AstraZeneca launch strategic manufacturing partnership

By Rachel Arthur contact

- Last updated on GMT

AstraZeneca: 'This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities' Pic:getty/oatawa
AstraZeneca: 'This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities' Pic:getty/oatawa

Related tags: Astrazeneca, Samsung biologics, South korea

Samsung Biologics and AstraZeneca have announced a $330.8m long-term global supply agreement: helping AstraZeneca expand biologics manufacturing capabilities in Asia Pacific.

Samsung Biologics will provide large-scale commercial manufacturing for drug substance at its Plant 3 site in South Korea. Situated in Songdo, Incheon, the facility was opened in 2018 and is the world’s largest single bio manufacturing plant.

The South Korean CDMO will also provide drug product to support AstraZeneca’s biologics therapeutics.

The agreement could be expanded to $545.6m. 

In partnering with Samsung Biologics, AstraZeneca will be able to expand its biologics manufacturing capabilities in Asia Pacific. The agreement is also expected to accelerate Korean bio-health innovation, according to the two companies.

Pam Cheng, EVP Global Operations & IT, AstraZeneca, said: "This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency.” 

Dr. Tae Han Kim, CEO of Samsung Biologics, said: "We are very proud to partner with AstraZeneca, a company that uses a rich history of science-led innovation to serve patients. At Samsung Biologics, our people share this common purpose to help our clients bring innovative solutions to an array of diseases, and we look forward to delivering on our promise to aid in AstraZeneca's ongoing expansion program."

AZ_SBL
A LOI signing event was held in June at Samsung Biologics' Incheon HQ. In attendance were Samsung Biologics CEO Tae Han Kim & AstraZeneca Korea's country president Juno Kim; and South Korean government officials Mr. Jae Joon Kim (Director of Bio-Convergence Industry from Ministry of Trade, Industry, & Energy) and Ms. Tae Gil Jung (Director of Division of Health Industry Promotion from Ministry of Health & Welfare) Leif Johansson, Chairman of the Board & Margareta Ozolins Nordvall, Senior Vice President Supply APAC of AstraZeneca joined the event via a virtual meeting platform.

Related topics: Downstream Processing

Related news

Show more

Follow us

Products

View more

Webinars